Drugs / RSLV-132
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02194400 | Jul 2014 → Nov 2015 | systemic lupus erythematosus | Resolve Therapeutics | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT06440525 | Dec 2024 → Dec 2026 expected | Sjogren syndrome | Resolve Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT04944121 | Jun 2021 → Oct 2023 | long COVID-19 | Resolve Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02660944 | Jan 2016 → May 2020 | systemic lupus erythematosus | Resolve Therapeutics | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03247686 Comparator | Feb 2017 → Jul 2018 | Sjogren syndrome | Resolve Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSLV-132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02194400 ↗ |
| Modality | Protein / enzyme biologic | “RNase-Fc fusion protein” NCT02660944 ↗ |
| Route | Intravenous | “Multiple Intravenous Doses” NCT02194400 ↗ |